Influenza Cell-Culture Vaccine Production

Hilleringmann, Markus; Jobst, Björn; Baudner, Barbara C.

doi:10.1007/978-3-319-00978-0_26

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baxter licensed in Europe Celvapan, a Vero cell-derived pandemic vaccine based on a wild-type "A/California/04/2009 (H1N1pdm09)"strain, in October 2009. 12,19 Preflucel, also manufactured by Baxter, is a seasonal influenza vaccine based on a Vero cell-line platform to produce three inactivated influenza viruses, including the A/H1N1 pandemic strain. During the 2008-2009 influenza season, a Phase III clinical study of Preflucel was conducted in the US.…”

Section: Cell Culture-derived Vaccinesmentioning

confidence: 99%

Cell culture-derived flu vaccine: Present and future

Rubio

Eiros

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.

show abstract

Section: Cell Culture-derived Vaccinesmentioning

confidence: 99%

Cell culture-derived flu vaccine: Present and future

Rubio

Eiros

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In contrast to egg-based production processes, cell-based production technology allows manufacturers to respond to market needs faster and in shorter production cycles and also allows a greater surge capacity, greater process control, and a more reliable and well-characterized product. Cell-based production allows manufacturers to supply higher quantities of the vaccines in a shorter amount of time [ 22 – 24 ]. Moreover, the virus obtained in cell cultures has a higher similarity with the circulating strains, in contrast with the virus produced in eggs, which might have antigenic modifications [ 25 – 27 ].…”

Section: Introductionmentioning

confidence: 99%

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines

Milián

Kamen

2015

BioMed Research International

128

142

View full text Add to dashboard Cite

Annually, influenza virus infects millions of people worldwide. Vaccination programs against seasonal influenza infections require the production of hundreds of million doses within a very short period of time. The influenza vaccine is currently produced using a technology developed in the 1940s that relies on replicating the virus in embryonated hens' eggs. The monovalent viral preparation is inactivated and purified before being formulated in trivalent or tetravalent influenza vaccines. The production process has depended on a continuous supply of eggs. In the case of pandemic outbreaks, this mode of production might be problematic because of a possible drastic reduction in the egg supply and the low flexibility of the manufacturing process resulting in a lack of supply of the required vaccine doses in a timely fashion. Novel production systems using mammalian or insect cell cultures have emerged to overcome the limitations of the egg-based production system. These industrially well-established production systems have been primarily selected for a faster and more flexible response to pandemic threats. Here, we review the most important cell culture manufacturing processes that have been developed in recent years for mass production of influenza vaccines.

show abstract

Escherichia coli expression of NDV fusion protein gene and determination of its antigenic epitopes

et al. 2015

View full text Add to dashboard Cite

Recurrent outbreaks of Newcastle disease have questioned the usage of existing vaccines that whether they are still adequate to protect clinical diseases and inhibit virus transmission in poultry. Advancement in molecular biology has led to the production of recombinant vaccines in recent years, which can be a more useful strategy to control infections of Newcastle disease virus (NDV). Studies indicate that the pathogenic nature of NDV is mediated by its membrane associated fusion (F) protein. Here we report the cloning of the full-length F gene-pET30a and its expression in Escherichia coli BL21 DE3 cells through isopropyl β-D-1-thiogalactopyranoside induction. Transferring the protein on nitrocellulose membrane in Western blotting confirmed its specificity with histidine-tagged antibody reaction at the proper size of 67 kDa. Protein purification with nickel charged sepharose column affinity chromatography resulted in a single band of 67 kDa purified His-tag F protein on SDS-PAGE. Analysis of its immunogenicity through bioinformatics tools revealed that more than 70% of its sequence is antigenically active comprising 24 linear immunogenic peptides predicted by the Linear epitope prediction tool and 9 immunogenic peptides predicted by ElliPro. This is a key achievement of the study, which may lead towards recombinant vaccine production in future. In conclusion, our findings suggest that rather than employing live viral vaccines, using a purified immunogenic recombinant F protein as a vaccine or cloning the same gene in a suitable plant vector for production of edible vaccine will provide better protection against the NDV into chicken.

show abstract

Influenza Cell-Culture Vaccine Production

Cited by 4 publications

References 46 publications

Cell culture-derived flu vaccine: Present and future

Cell culture-derived flu vaccine: Present and future

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines

Escherichia coli expression of NDV fusion protein gene and determination of its antigenic epitopes

Contact Info

Product

Resources

About